Home
About us
Projects
- SpagoPix
- Tumorad
Nanomedicine
- The EPR-effect
- Companion Diagnostics
Publications
Investors
Media
Contact

Home
About us
Projects
- SpagoPix
- Tumorad
Nanomedicine
- The EPR-effect
- Companion Diagnostics
Publications
Investors
Media
Contact

Redeye

Analyst: Klas Palin
klas.palin@redeye.se

Latest research on Spago Nanomedical

Spago Nanomedical develops nanomaterials for improved cancer diagnostics and treatment

News

Spago Nanomedical participates in EU NANO2ALL project
Apr 25 2018
SpagoPix featured in international media
Oct 5 2017
FDA votes for further warnings for gadolinium-based contrast agents
Sep 11 2017

Press releases

US patent granted for Tumorad®
Jun 26 2018
Spago Nanomedical select CTC for the first clinical trial with SpagoPix
May 28 2018
SpagoPix shows good safety in regulatory preclinical studies
May 24 2018

Copyright

© 2016 Spago Nanomedical AB.
All rights reserved

Address

Scheelevägen 22
SE-223 63 Lund, Sweden

LinkedIn

Home
About us
Projects
Nanomedicine
Publications
Investors
Media
Contact